BMRN
Biomarin Pharmaceutical Inc
62.20$
-1.8%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | +138.8% | +76.9% | +256.7% | -42.2% | -9.5% | +259.7% | +44.5% | |
| – | -16.8% | +105.4% | -9.3% | +8.9% | +10.1% | -0.1% | +2.7% | -5.6% | +2.4% | -7.6% | -17.5% | |
| – | +26.4% | +20.7% | +4.2% | +6.1% | +7.4% | +18.7% | +4.0% | -0.5% | +5.5% | -2.7% | -10.0% | |
| – | -626.6% | – | -83.0% | -75.2% | +188.7% | -1,285.3% | – | -84.5% | – | – | – | |
| – | – | -445.9% | – | – | – | – | – | -246.0% | – | – | – | |
| – | +91.6% | -34.8% | +34.3% | -27.4% | +0.3% | -5.2% | -13.3% | +1.5% | -11.0% | -9.5% | +5.8% | |
| – | -706.3% | -59.0% | -36.9% | – | -111.7% | +72.8% | +583.2% | -94.5% | +455.4% | – | -403.5% | |
| – | – | – | – | – | – | +549.7% | -95.3% | +344.1% | – | – | – | |
| – | +195.9% | +158.7% | -43.7% | +7.2% | +18.8% | +17.2% | -8.4% | +18.5% | +40.6% | +1.6% | – | |
| – | -75.8% | – | +0.0% | -177.8% | -98.6% | – | -101.4% | -14.3% | -100.0% | – | -100.0% | |
| – | +399.7% | -21.6% | -30.3% | -176.5% | -80.8% | – | -100.0% | +38,754.2% | +0.4% | +2,711.2% | -91.9% | |
| – | -256.0% | – | +1,580.2% | -154.8% | – | – | -129.2% | – | -77.7% | +513.5% | +96.5% | |
| – | – | – | – | – | – | – | – | -70.4% | -6.0% | +820.5% | +52.5% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.